Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. It is advancing a deep and sustainable product portfolio of 18 gene therapy product candidates, with exclusive options to acquire four additional development programs. Its product candidates include TSHA-101, TSHA-118, TSHA-102, TSHA-103, and TSHA-104
This is not a financial advice!
Upcoming catalyst on 31st. of March
We need to stay in a bullish overal sentiment of the market. If we see a corretion, this play might doesn't work.
13% short float
Rel. Vol. at 3.13
Block buys and Passive Stakes
Keep an eye on 2.0, 2.50, 3.0, 3.9 and 5.0 level, needs to get broken for a further upmove. You can take partial profits at these levels if u want to lock in gains.
SL under 1.10
TP approx. 5.0
Most info on the chart.
Trade carefully!